REGN FY 2011 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$79B

FY 2011 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$446M-2.9% YoY

Gross Profit

$411M92.1% margin

Operating Income

-$205M-46.0% margin

Net Income

-$222M-49.7% margin

EPS (Diluted)

$-2.45

Cash Flow

Operating Cash Flow

-$142M

Free Cash Flow

-$199M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$838M

Stockholders' Equity

$486M

Cash & Equivalents

$484M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$446M	$459M	-2.9%
Gross Profit	$411M	$437M	-6.1%
Operating Income	-$205M	-$97M	-110.5%
Net Income	-$222M	-$104M	-112.3%